Ablynx N.V. | Cash Flow

Fiscal year is January-December. All values EUR Millions.
2013
2014
2015
2016
2017
Net Income before Extraordinaries
3,716
4,390
4,287
4,709
8,434
Depreciation, Depletion & Amortization
5,569
3,280
4,276
3,301
3,119
Other Funds
12
4
35
89
15
Funds from Operations
6,818
6,782
7,865
7,356
7,231
Changes in Working Capital
136
908
1,055
828
148
Net Operating Cash Flow
6,954
7,690
8,920
8,184
7,379
Capital Expenditures
1,398
1,453
2,772
2,083
1,956
Sale of Fixed Assets & Businesses
409
264
211
209
535
Purchase/Sale of Investments
18
571
142
208
161
Net Investing Cash Flow
1,313
3,458
3,265
2,648
602
Cash Dividends Paid - Total
3,638
3,676
3,694
3,759
3,710
Issuance/Reduction of Debt, Net
599
390
1,346
2,293
2,297
Net Financing Cash Flow
3,686
5,182
3,593
3,979
7,865
Net Change in Cash
1,876
916
1,830
1,456
42
Free Cash Flow
5,858
6,237
6,148
6,101
5,423
Deferred Taxes & Investment Tax Credit
1,010
1,151
1,253
542
909
Net Assets from Acquisitions
275
1,723
228
437
1,188
Other Sources
-
128
-
-
3,535
Change in Capital Stock
635
1,120
1,210
2,602
1,843
Exchange Rate Effect
79
34
232
101
74
Other Uses
31
103
334
129
163

About Ablynx

View Profile
Address
54, rue La Boétie
Paris Ile-de-France 75008
France
Employees -
Website http://www.sanofi.com
Updated 09/14/2018
Sanofi engages in the research, production and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Human Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes & cardiovascular, established prescription products and generics, together with research, development and production activities.